Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q3 2023 · 10-Q
Revenue$305.30M$305.30M+17.5% vs Q3 2022 Net Income$32.94M$32.94M+41.8% vs Q3 2022 EPS Diluted$0.64$0.64+42.2% vs Q3 2022 Gross Profit$158,707,000+14.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$64,415,000+3.2% Free Cash Flowderived$47,567,000+33.0% Margins · derivedGross margin52.0%−1.4 pt vs Q3 2022
Operating margin14.2%+0.5 pt vs Q3 2022
Net margin10.8%+1.8 pt vs Q3 2022
ended Dec 31, 2022 · filed Feb 7, 2023 · 38 d after period end